Profile data is unavailable for this security.
About the company
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.
- Revenue in USD (TTM)380.79m
- Net income in USD49.27m
- Incorporated2014
- Employees384.00
- LocationAmylyx Pharmaceuticals Inc43 THORNDIKE STREETCAMBRIDGE 02141United StatesUSA
- Phone+1 (617) 682-0917
- Fax+1 (302) 636-5454
- Websitehttps://www.amylyx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 125.94m | 37.00 | -- | 1.02 | -- | 120.83 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| Karyopharm Therapeutics Inc | 146.03m | -143.10m | 128.11m | 325.00 | -- | -- | -- | 0.8773 | -1.25 | -1.25 | 1.28 | -1.19 | 0.4879 | 1.36 | 3.94 | 449,332.30 | -47.81 | -53.02 | -61.78 | -65.85 | 96.62 | 97.18 | -97.99 | -125.15 | 3.32 | -10.06 | 1.81 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Hongchang International Co Ltd | 2.68m | -378.79k | 129.76m | 8.00 | -- | 3.20 | -- | 48.49 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Vaxart Inc | 7.38m | -82.47m | 130.58m | 109.00 | -- | 1.96 | -- | 17.70 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 132.09m | 13.00 | -- | 10.26 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| FitLife Brands Inc | 52.70m | 5.30m | 133.30m | 37.00 | 26.81 | 4.93 | 24.73 | 2.53 | 1.08 | 1.08 | 10.74 | 5.88 | 1.30 | 3.44 | 38.31 | 1,424,297.00 | 13.07 | 26.40 | 15.94 | 33.92 | 40.67 | 42.09 | 10.05 | 17.65 | 0.5419 | 16.81 | 0.4253 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Amylyx Pharmaceuticals Inc | 380.79m | 49.27m | 133.97m | 384.00 | 2.80 | 0.3077 | 2.66 | 0.3518 | 0.7045 | 0.7045 | 5.43 | 6.40 | 0.8379 | 1.06 | 13.76 | 991,630.20 | 10.84 | -- | 12.63 | -- | 93.32 | -- | 12.94 | -- | 5.20 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| FibroGen Inc | 167.49m | -240.46m | 136.28m | 486.00 | -- | -- | -- | 0.8137 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 137.40m | 53.00 | 8.85 | 2.96 | 8.13 | 2.90 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Syros Pharmaceuticals Inc | 9.94m | -164.57m | 137.65m | 68.00 | -- | 8.17 | -- | 13.86 | -5.77 | -5.77 | 0.3508 | 0.63 | 0.0482 | -- | 11.73 | 146,102.90 | -79.76 | -54.44 | -95.35 | -64.32 | -- | -- | -1,656.51 | -772.82 | -- | -- | 0.7122 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Sagimet Biosciences Inc | 2.00m | -27.88m | 138.19m | 10.00 | -- | 1.09 | -- | 69.10 | -1.31 | -1.31 | 0.0937 | 3.98 | -- | -- | -- | 200,000.00 | -- | -- | -- | -- | -- | -- | -1,393.80 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -42.94m | 138.46m | 25.00 | -- | 4.78 | -- | -- | -1.39 | -1.39 | 0.00 | 0.7896 | 0.00 | -- | -- | 0.00 | -62.97 | -51.63 | -76.04 | -59.00 | -- | -- | -- | -- | -- | -33.04 | 0.4772 | -- | -- | -- | -5.11 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.38m | 138.93m | 18.00 | -- | 2.72 | -- | -- | -0.6168 | -0.6168 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -43.77 | -45.38 | -46.37 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00008 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Repare Therapeutics Inc | 51.13m | -93.80m | 139.22m | 179.00 | -- | 0.6523 | -- | 2.72 | -2.23 | -2.23 | 1.21 | 5.03 | 0.1655 | -- | 5.21 | 285,659.20 | -30.36 | -23.40 | -37.50 | -26.37 | -- | -- | -183.44 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Data as of May 08 2024. Currency figures normalised to Amylyx Pharmaceuticals Inc's reporting currency: US Dollar USD
40.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.14m | 7.59% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.68m | 5.43% |
| Viking Global Investors LPas of 31 Dec 2023 | 2.96m | 4.37% |
| Point72 Asset Management LPas of 31 Dec 2023 | 2.77m | 4.08% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.73m | 4.02% |
| Stonepine Capital Management LLCas of 31 Dec 2023 | 2.50m | 3.69% |
| Millennium Management LLCas of 31 Dec 2023 | 2.27m | 3.35% |
| Citadel Advisors LLCas of 31 Dec 2023 | 1.97m | 2.90% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 1.87m | 2.76% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.44m | 2.13% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
